新抗体步骤提高阿尔茨海默病血液检测可靠性
Added antibody step improves the reliability of Alzheimer's blood tests
德国哈勒大学医学院研究人员开发了一种新方法,通过抗体分离脑源性tau蛋白,提高了阿尔茨海默病血液检测的准确性。研究在315名参与者中验证了该方法,发现其能更准确地区分阿尔茨海默病与其他疾病。该方法有助于减少误诊,提高早期诊断的可靠性。
Researchers at University Medicine Halle have developed a new method that could improve the reliability of blood tests for Alzheimer's disease. Current commercial tests often rely on the protein biomarker p-tau217, whose levels can rise in the early stages of the disease. However, the biomarker levels can also be elevated in other conditions, potentially leading to false-positive results. In a study involving 315 participants, the research team demonstrated improved accuracy in distinguishing Alzheimer's disease from other conditions. Their findings have been published in Nature Communications.
Early and accurate diagnosis is crucial for patients who may benefit from recently approved antibody treatments for Alzheimer's disease, as these therapies must be initiated in the early stages of the disease. Blood tests are one promising diagnostic tool, offering considerable potential for identifying these patients. Many of these tests measure a phosphorylated form of the tau protein known as p-tau217. Blood levels of this biomarker can rise long before severe cognitive symptoms, such as short-term memory impairments, appear.
Other conditions can raise tau levels
However, in 2025, neurologists at University Medicine Halle demonstrated that elevated levels of this biomarker alone are not a reliable indicator of Alzheimer's disease. They also found elevated levels in people with amyotrophic lateral sclerosis (ALS), a disease affecting the motor nervous system. Diseases affecting the brain, the nerves or the muscles may therefore contribute to increased biomarker levels in the blood.
The tau protein exists in several forms. Smaller forms, known as "brain-derived tau," occur mainly in the brain, while a larger form, known as "big tau," is found in peripheral nerves, muscles and possibly other tissues. "Conventional blood tests cannot reliably distinguish between these different forms of tau," explains professor Markus Otto, director of the Department of Neurology at University Medicine Halle and senior author of the study. "Consequently, elevated p-tau217 levels may incorrectly indicate Alzheimer's disease when they are actually associated with a muscle or nerve disorder."
Isolating tau from the brain
To address this issue, a research team led by Otto developed a method to improve the diagnostic accuracy of the established p-tau217 blood test. The new approach has two steps. First, a specific antibody is used to isolate brain-derived tau from the blood sample before it is measured.
The researchers then compared the conventional test with the new method using blood samples from 315 participants: 101 people with Alzheimer's disease, 139 people with ALS and 75 control participants. The samples were collected at neurological centers in Halle and Mannheim, Germany, and Milan, Italy.
The conventional test indicated elevated p-tau217 levels in both the Alzheimer's and ALS groups. When the additional antibody step was included, however, the picture changed: "p-tau levels were elevated in people with Alzheimer's disease, but not in those with ALS or in the control group," explains Dr. Samir Abu Rumeileh, consultant neurologist at the Department of Neurology at University Medicine Halle and first author of the study. "In our cohort, the method therefore clearly distinguished between the two diseases."
Clinical promise still needs validation
Comparative analyses of brain, spinal cord and muscle tissue conducted using mass spectrometry helped explain these results. Brain-derived p-tau217 was virtually absent from muscle tissue. This indicates that brain-derived p-tau217 measured in the blood originates from the brain and reflects Alzheimer's-related changes there. The researchers therefore propose using the new method alongside existing blood tests in clinical practice.
"A conventional p-tau217 test could provide a first indication of Alzheimer's disease. If the result does not fit the clinical picture, or if a muscle or nerve disorder might be influencing the measurement, the two-step method can help clarify the result. This would reduce false-positive results and help identify more reliably the patients who are eligible for the new Alzheimer's therapies," says Abu Rumeileh.
These findings could also have implications for ALS research. In the future, blood tests that target the large tau forms could help researchers evaluate muscle and nerve damage in people with ALS and track disease progression without requiring invasive procedures.
Additional research is necessary before the new method can be adopted for widespread clinical use. The measurement process must first be standardized and validated in larger, independent patient cohorts. Nevertheless, the research team believes that the method has the potential to become part of routine diagnostics.
Publication details
Samir Abu-Rumeileh et al., Tau isoform mapping across tissues and biofluids reveals a signature distinguishing Alzheimer's disease from amyotrophic lateral sclerosis, Nature Communications (2026). DOI: 10.1038/s41467-026-78390-3
Journal information: Nature Communications
Who's behind this story?
Gaby Clark
MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: Added antibody step improves the reliability of Alzheimer's blood tests (2026, October 26) retrieved 26 October 2026 from https://medicalxpress.com/news/2026-10-added-antibody-reliability-alzheimer-blood.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com